On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
MondayJul 18, 2016 3:43 pm

Laguna Blends, Inc. (CSE: LAG) (LB6A.F) (OTC: LAGBF) Highlights Recent Milestones Related to Growth Strategy

Before the opening bell, Laguna Blends, Inc. (OTC: LAGBF) issued a news release recapping some of its recent milestones related to its planned entry into the $121 billion global skin care industry. The most recently announced milestone related to this goal was the company’s entry into a non-binding letter of intent to acquire the exclusive license brand name and existing inventory of CannaCeuticals of California, USA (“Canna”), which was originally announced in a news release issued on July 7. Under the terms of this agreement, Laguna will receive an exclusive license to sell Canna’s cannabidiol (CBD) skin care products in…

Continue Reading

WednesdayJul 06, 2016 5:19 pm

Laguna Blends, Inc. (CSE: LAG) (LB6A.F) (OTC: LAGBF) Enters Letter of Intent to Acquire Exclusive Distribution Rights for Cannabidiol Skin Care Line

Before the opening bell, Laguna Blends, Inc. (OTC: LAGBF) announced the execution of a non-binding letter of intent with Cannaceuticals of California, USA (Canna) through which it plans to enter into a definitive manufacturing and exclusive license agreement for Canna’s cannabidiol (CBD) skin care line. The two parties have agreed to an exclusivity period running through July 29, during which additional negotiations and signing of the manufacturing and license agreement are expected to take place. “Canna has spent a tremendous amount of time and financial resources to create what we believe is the highest quality CBD skin care line available…

Continue Reading

TuesdayJul 05, 2016 5:23 pm

Cesca Therapeutics, Inc. (KOOL) Advancing the Practice of Cell Therapy for Regenerative Medicine

Cesca Therapeutics, Inc. (NASDAQ: KOOL) describes itself as being “engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine.” The company focuses on three markets: therapies, medical and diagnostic devices, and cell manufacturing and banking services. Most recently, the company’s CLIRST III trial was approved by the U.S Food and Drug Administration (FDA). The CLIRST III trial is being undertaken to determine the safety and efficacy of Cesca’s SurgWerks-CLI platform. This platform is for the treatment of people with late-stage, no option or critical limb ischemia (CLI). The CLIRST III clinical study “is a prospective,…

Continue Reading

Contact us: 303.498.7722